Home › Lymphoma › Massachusetts › Boston
Pag-aaral pangklinika para sa Lymphoma sa Boston, MA
34 pag-aaral para sa Lymphoma ang naghahanap ng mga kalahok sa mga site sa loob at paligid ng Boston (sa loob ng humigit-kumulang 30 milya). Buksan ang pag-aaral upang makita kung sino ang makakasali at kung paano makipag-ugnayan sa koponan ng pag-aaral.
Opisyal na teksto ng pag-aaral (English)
A Study of Pembrolizumab (MK-3475) in Pediatric Participants With an Advanced Solid Tumor or Lymphoma (MK-3475-051/KEYNOTE-051)
Nagre-recruitPhase 1/2
- Call for Information (Investigational Site 0026), Boston
A Phase 2 Study of Epcoritamab in Patients With Follicular Lymphoma and Marginal Zone Lymphoma Not Accomplishing a Complete Response With Upfront Therapy
Nagre-recruitPhase 2
- Beth Israel Deaconess Medical Center, Boston
A Study of the Efficacy and Safety of Lisocabtagene Maraleucel (Liso-cel) as First-Line Therapy in Adults With Transplant-Ineligible Primary Central Nervous System Lymphoma
Nagre-recruitPhase 2
- Dana-Farber Cancer Institute, Boston
A Study to Investigate Ronde-cel Versus Investigator's Choice CD19 CAR T-Cell Therapy
Nagre-recruitPhase 3
- Tufts Medical Center, Boston
HEME Home Transfusion Program
Nagre-recruit
- Brigham and Women's Hospital, Boston
- Dana-Farber Cancer Institute, Boston
A Resilience-Based Approach to Improve Long-term Quality of Life in Post-treatment Lymphoma Survivorship
Nagre-recruit
- Mass General Hospital, Boston
Pembrolizumab + Chemotherapy in Newly Diagnosed PCNSL
Nagre-recruitPhase 1
- Brigham and Women's Hospital, Boston
- Dana Farber Cancer Institute, Boston
GLORY: Glofit-GemOx With Liso-Cel For Lymphoma
Nagre-recruitPhase 2
- Massachusetts General Hospital, Boston
- Beth Israel Deaconess Medical Center, Boston
AZD3470 as Monotherapy or in Combination With Anticancer Agent(s) in Participants With Haematologic Malignancies.
Nagre-recruitPhase 1/2
- Research Site, Boston
CA-4948-101: Open-Label, Dose Escalation and Expansion Trial of Emavusertib (CA-4948) in Relapsed or Refractory Primary Central Nervous System Lymphoma (R/R PCNSL)
Nagre-recruitPhase 1/2
- Dana Farber Cancer Institute, Boston
Surovatamig as Consolidation Therapy in Participants With Chronic Lymphocytic Leukaemia or Small Lymphocytic Lymphoma With Unmutated Immunoglobulin Heavy Chain Variable (IGHV)
Nagre-recruitPhase 3
- Research Site, Boston
A First-in-Human Study of KK2223 in Participants With Relapsed or Refractory T Cell Non-Hodgkin Lymphoma
Nagre-recruitPhase 1
- Beth Israel Deaconess Medical Center - Research, Boston
Increasing Resiliency Among Early Post-Treatment Lymphoma Survivors
Nagre-recruit
- Mass General Brigham, Boston
A Study of Repotrectinib in Pediatric and Young Adult Subjects Harboring ALK, ROS1, OR NTRK1-3 Alterations
Nagre-recruitPhase 1/2
- Dana Farber Cancer Institute., Boston
Epco, Zanu, Ritux for R/R FL or MZL
Nagre-recruitPhase 2
- Dana-Farber Cancer Institute, Boston
CBL0137 for the Treatment of Relapsed or Refractory Solid Tumors, Including CNS Tumors and Lymphoma
Nagre-recruitPhase 1/2
- Dana-Farber Cancer Institute, Boston
Study of SLS009 (Formerly GFH009) a Potent Highly Selective CDK9 Inhibitor in Patients With Hematologic Malignancies and High-Risk Newly Diagnosed AML
Nagre-recruitPhase 1/2
- Massachusetts General Hospital, Boston
A Study of Tulmimetostat DZR123 (CPI-0209) in Patients With Advanced Solid Tumors and Lymphomas
Nagre-recruitPhase 1/2
- Massachusetts General Hospital, Boston
Cosibelimab for CSCC in Patients With Kidney Transplant or Hematologic Malignancy
Nagre-recruitPhase 4
- Brigham and Women's Hospital, Boston
- Dana-Farber Cancer Institute, Boston
DALY II USA/ MB-CART2019.1 for DLBCL
Nagre-recruitPhase 2
- Dana Farber Cancer Institute, Boston
A Study of DR-01 in Subjects With Large Granular Lymphocytic Leukemia or Cytotoxic Lymphomas
Nagre-recruitPhase 1/2
- Dren Investigational Site, Boston
Effects of Dexrazoxane Hydrochloride on Biomarkers Associated With Cardiomyopathy and Heart Failure After Cancer Treatment
Nagre-recruitObservasyonal na pag-aaral
- Dana-Farber Cancer Institute, Boston
Remote Monitoring and Symptom Management Digital Application
Nagre-recruit
- Massachusetts General Hospital, Boston
Defining the Role of Palliative carE for Patients With Hematologic Malignancies Undergoing Adoptive CEllular Therapy
Nagre-recruit
- Massachusetts General Hospital Cancer Center, Boston
Interrupting Sedentary Time to Improve Cardiometabolic Health and Toxicity in Patients With Lymphoma Receiving Chemotherapy: The iSTAND Trial
Nagre-recruit
- Dana Farber Cancer Institute, Boston
A Platform Protocol to Investigate Post-Transplant Cyclophosphamide-Based Graft-Versus-Host Disease Prophylaxis in Patients With Hematologic Malignancies Undergoing Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation
Nagre-recruitPhase 2
- Dana-Farber Cancer Institute, Boston
Odronextamab in Low Tumor Volume Advanced FL
Nagre-recruitPhase 2
- Beth Israel Deaconess Medical Center, Boston
Rituximab Plus Venetoclax in Front Line Marginal Zone Lymphoma
Nagre-recruitPhase 2
- Beth Israel Deaconess Medical Center, Boston
A Phase II Study of Glofitamab Plus Polatuzumab-R-CHP for Patients With High-risk Diffuse Large B-cell Lymphoma
Nagre-recruitPhase 2
- Beth Israel Deaconess Medical Center, Boston
- Dana Farber Cancer Institute, Boston
BRAZAN: A Randomized Phase 2 Study of Bendamustine, Rituximab, Cytarabine (AraC) Induction With Zanubrutinib (BRAZAN) Followed by Zanubrutinib/Rituximab +/- Sonrotoclax Maintenance in Treatment-Naïve Mantle Cell Lymphoma
Nagre-recruitPhase 2
- Beth Israel Deaconess Medical Center, Boston
- Dana-Farber Cancer Institute, Boston
CONFIRM: Magnetic Resonance Guided Radiation Therapy
Nagre-recruit
- Brigham & Women's Hospital, Boston
- Dana Farber Cancer Institute, Boston
Avo In R/R And Previously Untreated MCL
Nagre-recruitPhase 1/2
- Beth Israel Deaconess Medical Center, Boston
- Dana-Farber Cancer Institute, Boston
Mosunetuzumab for CLL MRD Clearance
Nagre-recruitPhase 1/2
- Brigham & Women's Hospital, Boston
- Dana-Farber Cancer Institute, Boston
A Phase 2 Study to Evaluate the Safety and Efficacy of Pacritinib in Relapsed or Refractory Waldenström Macroglobulinemia
Nagre-recruitPhase 2
- Dana Farber Cancer Institute, Boston
Pag-aaral para sa Lymphoma sa ibang lungsod
- Houston, TX34 pag-aaral
- New York City, NY33 pag-aaral
- Washington, DC23 pag-aaral
- Baldwin Park, CA22 pag-aaral
- Chicago, IL19 pag-aaral
- Durham, NC17 pag-aaral
- St. Louis, MO15 pag-aaral
- Cleveland, OH13 pag-aaral
- Seattle, WA13 pag-aaral
- Atlanta, GA13 pag-aaral
- Philadelphia, PA13 pag-aaral
- Edison, NJ12 pag-aaral
Iba pang pag-aaral sa Boston
- Kanser sa Suso110 pag-aaral
- Kanser (lahat ng uri)90 pag-aaral
- Non-Small Cell Lung Cancer87 pag-aaral
- Kanser sa Baga63 pag-aaral
- Colorectal Cancer62 pag-aaral
- Kanser sa Ovary62 pag-aaral
- Metastatic Cancer61 pag-aaral
- Kanser sa Prostate56 pag-aaral
- Kanser ng Endometrium51 pag-aaral
- Depression50 pag-aaral
- Pagkabigo ng Puso46 pag-aaral
- Multiple Myeloma45 pag-aaral
Mula sa ClinicalTrials.gov, na-kuha noong Nob 15, 2026. Ang bawat pag-aaral ay may sariling pamantayan sa eligibility; ang koponan ng pag-aaral ang magdedesisyon kung sino ang makakasali.